Purchase any webinar and get OFF
Recorded Webinar
SIGNUP AND FLAT OFF ON WEBINAR.
All Days
Choose Your Options
Expectations for meaningful hazard analysis, hazardous conditions, and documentation have always existed by regulatory agencies. There is an increased awareness of the importance of design activities to support the production of safe and effective products. Product Risk Management (always required) and Human Factors / Use Engineering (not always required) are the tools to drive and direct resource-constrained product design, manufacture, and validation activities in the company. To this has been added the requirement to add risk management to important QMS activities as spelled out in the 2019 version of ISO 14971. High-profile field problems indicate that such activities are not yet adequately planned, executed, and visibility maintained. There is a failure to fully utilize the power of current risk management / human factors tools. Effective use of such tools can help address the growing push by the public and the FDA to “toughen” its approach to product clearance and approval, while reducing liability issues. Two suggested Field-tested and Agency / EU audited "model" formats will be presented, suitable to meet both US FDA CGMP and EU regulatory requirements. Additional assistance in developing UE/HF tests can be provided by HEP tools.
Areas Covered
Background
How to develop, modify, and use the tools of the User/Patient Device Risk Management File per ISO 14971:2019 (a major requirement of the new QMSR), Pharma's ICH Q9, and Error Reduction with IEC 62366-1, Usability Engineering, with added HEP considerations.
Why Should You Attend
The U.S. FDA has stated that the use of a medical device or pharmaceuticals entails some degree of risk. In fact, any medical procedure/intervention does. A manufacturer is responsible for identifying those risks, and potential "use errors", and taking reasonable steps to mitigate them as far as practical and given the ‘state of the art’ at the time. ISO 14971, ICH Q9 (risk), and IEC 62366 (use / human factors) provide accepted methodologies by which to perform and document such an analysis, and are accepted by the FDA. These activities can also be used as a method to train new hires, especially in Marketing, QA/RA, Engineering, and Manufacturing. This webinar will address the procedures, provide and discuss suggested templates, necessary to develop or modify, and then use the ISO 14971, Q9, and IEC 62366 models to perform and document such activities for any medical product. It will examine the additional actions necessary to make them useful product references, CAPA, root cause/failure investigation, validation prioritization, and training tool, and how to maintain it as a “living document”. The latest change in ISO 14971:2019 will also be considered and discussed, including its expansion to include a company's entire QMS. How HEP can assist, especially in developing Useability tests.
Who Should Attend
John E. Lincoln is the Principal of J. E. Lincoln and Associates, a consulting company with over 41 years of experience in U.S. FDA-regulated industries, 27 of which as head of his own consulting company. John has worked with companies from start-ups to Fortune 100, in the U.S., Mexico, Canada, France, Germany, Sweden, China, and Taiwan. He specializes in quality assurance, regulatory affairs, QMS problem remediation, FDA responses, new/changed product 510(k)s, process/product/equipment incl+D33uding QMS and software validations, ISO 14971 product risk management files/reports, Design Control / Design History Files, Technical Files. He's held Manufacturing Engineering, QA, QAE, and Regulatory Affairs positions at the Director and VP (R&D) levels. In addition, John has prior experience in the military, government, electronics, and aerospace. He has published numerous articles in peer-reviewed journals, including 5 chapters in the RAPs validation textbook, and conducted workshops and webinars worldwide on regulatory issues. John is a graduate of UCLA.